ArticleBiomedical journal2026
The role of blue light-filtering and premium intraocular lenses on postoperative falls: A nationwide target trial emulation in Taiwan.
Article in Biomedical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Displaced minds: ecologies of depression.Biomedical journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFalls are a leading cause of injury and premature death in older adults, and cataract surgery reduces fall risk. Concerns existed that blue-light filtering (BF) intraocular lenses (IOLs) might impair light transmittance and increase fall risk. We aimed to compare fall incidence and injury diagnoses among patients who received bilateral cataract surgery with premium BF, premium non-BF, and standard non-BF IOLs. MATERIAL AND
methodsWe emulated a target trial by enrolling 26,730 well-matched patients per IOL cohort who underwent bilateral cataract surgeries between 2011 and 2017 from the Taiwan National Health Insurance Research Database. They were followed until a fall, death, withdrawal, or December 31, 2022. Propensity score matching minimized baseline differences across groups.
resultsFall incidence increased over time, from 9.07 to 21.13 per 1000 person-years. The premium BF-IOL (12.94) and premium non-BF-IOL (13.12) groups had lower fall rates than the standard non-BF-IOL group (14.85). Both Cox and Fine-Gray models showed significantly lower fall risks for premium BF-IOL (HR 0.86, SHR 0.92) and premium non-BF-IOL (HR 0.88, SHR 0.91) compared to standard IOLs. There was no significant difference in fall risk between premium BF-IOL and premium non-BF-IOL (HR/SHR 0.99). While hospitalization rates post-fall (68.6 %) and 30-day fatal fall rate (1.29 %) were comparable, standard IOLs were associated with significantly higher fracture rates.
conclusionsWe found no evidence that BF-IOLs increase fall incidence. Both premium IOL groups consistently had lower fall rates than standard non-BF-IOLs, suggesting that socioeconomic factors, in addition to IOL type, may contribute to this reduction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.